COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,010 Articles (22,627 medRxiv, 8,383 bioRxiv)

Most recent first Previous |  Page 653: Articles 6521-6530  | Next

COVID-19 rebound after Paxlovid treatment during Omicron BA.5 vs BA.2.12.1 subvariant predominance period
Xu, R., Wang, L., Volkow, N. D., Davis, P. B., Berger, N. A., Kaelber, D. C.
10.1101/2022.08.04.22278450 — Posted: 2022-08-06
Finding a Needle in the Haystack: Design and Implementation of a Digital Site-less Clinical Study of Serial Rapid Antigen Testing to Identify Asymptomatic SARS-CoV-2 Infection
Soni, A., Herbert, C., Pretz, C., Stamegna, P., Filippaios, A., Shi, Q., Suvarna, T., Harman, E., Schrader, S., Nowak, C., Schramm, E., Kheterpal, V., Behar, S., Tarrant, S., Ferranto, J., Hafer, N., Robinson, M., Achenbach, C., Murphy, R., Manabe, Y. C., Barton, B., O'Connor, L., Fahey, N., Orvek, E., Lazar, P., Ayturk, D., Wong, S., Zai, A., Cashman, L., Rao, L. V., Luzuriaga, K., Lemon, S. C., Blodgett, A., Heetderks, W., Broach, J., McManus, D.
10.1101/2022.08.04.22278274 — Posted: 2022-08-05
The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern
Graham, C., Lechmere, T., Rehman, A., Seow, J., Kurshan, A., Huettner, I., Maguire, T. J. A., Tam, J., Cox, D., Ward, C., Racz, M., Waters, A., Mant, C., Malim, M. H., Fox, J., Doores, K. J.
10.1101/2022.08.04.22278160 — Posted: 2022-08-05
Human endogenous retrovirus-R envelope is a host restriction factor against severe acute respiratory syndrome-coronavirus-2
Gupta, N., Ansari, S., Verma, R., Singh, O. N., Yadav, M. K., Binayke, A., Jakhar, K., Mani, S., Awasti, A., Shalimar, , Nayak, B., Ranjith-Kumar, C., Surjit, M.
10.1101/2022.08.05.502940 — Posted: 2022-08-05
Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5
Tamura, T., Yamasoba, D., Oda, Y., Ito, J., Kamasaki, T., Nao, N., Hashimoto, R., Fujioka, Y., Suzuki, R., Wang, L., Ito, H., Kimura, I., Yokota, I., Kishimoto, M., Tsuda, M., Sawa, H., Yoshimatsu, K., Ohba, Y., Yamamoto, Y., Nagamoto, T., Kanamune, J., The Genotype to Phenotype Japan (G2P-Japan) Consortium, , Matsuno, K., Takayama, K., Tanaka, S., Sato, K., Fukuhara, T.
10.1101/2022.08.05.502758 — Posted: 2022-08-05
SARS-CoV-2 entry route impacts a range of downstream viral and cellular processes
Qu, B., Miskey, C., Goemer, A., Potmus, D., Nocke, M., Kleinert, R. D. V., Itotia, T. K., Valder, L., Brueckmann, J., Hoeck, S., Hastert, F. D., von Rhein, C., Schuermann, C., Ebenig, A., Widera, M., Ciesek, S., Pfaender, S., Ivics, Z., Schnierle, B. S., Tarr, A. W., Goffinet, C., Muehlebach, M. D., Todt, D., Brown, R. J. P.
10.1101/2022.08.05.502936 — Posted: 2022-08-05
mRNA vaccines and hybrid immunity use different B cell germlines to neutralize Omicron BA.4 and BA.5
Andreano, E., Paciello, I., Pierleoni, G., Maccari, G., Antonelli, G., Abbiento, V., Pileri, P., Benincasa, L., Giglioli, G., Piccini, G., De Santi, C., Sala, C., Medini, D., Montomoli, E., Maes, P., Rappuoli, R.
10.1101/2022.08.04.502828 — Posted: 2022-08-05
A specific anti-IFITM2 antibody bars the way to SARS-CoV-2 entry into host cells.
Basile, A., Zannella, C., De Marco, M., Franci, G., Galdiero, M., Sanna, G., Manzin, A., Chetta, M., Turco, M. C., Rosati, A., Marzullo, L.
10.1101/2022.08.04.502768 — Posted: 2022-08-04
Double-dose mRNA vaccination to SARS-CoV-2 progressively increases recognition of variants-of-concern by Spike RBD-specific memory B cells
Hartley, G. E., Edwards, E. S. J., Varese, N., Boo, I., Aui, P. M., Bornheimer, S. J., Hogarth, P. M., Drummer, H. E., O'Hehir, R. E., van Zelm, M. C.
10.1101/2022.08.03.502703 — Posted: 2022-08-04
"I don't know what to do or where to go". experiences of accessing healthcare support from the perspectives of people living with Long Covid and healthcare professionals: A qualitative study in Bradford, UK.
Baz, S. A., Fang, C., Carpentieri, J., Sheard, L.
10.1101/2022.08.04.22278204 — Posted: 2022-08-04

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).